BriaCell Starts Patient Enrollment In First-in-Human Study Of Bria-OTS In Advanced Metastatic Breast Cancer

5/30/24 8:09:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BCTX alert in real time by email

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell's personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab, in advanced metastatic breast cancer.

Get the next $BCTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCTX

Date	Price Target	Rating	Analyst
2/14/2022	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

$BCTX
Press Releases

Fastest customizable press release news feed in the world

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates both innate and adaptive immune systemsProof of concept Phase 1/2 Study of Bria-BRES™ in metastatic breast cancer currently underway PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next gen
11/8/24 7:50:53 AM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast
11/4/24 7:50:57 AM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple outperforming patients with overall survival of over 2 yearsSurvival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs) Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive No Bria-IMT™ related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCT
10/22/24 7:50:00 AM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care

$BCTX
Leadership Updates

Live Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2023 held on January 30, 2024 (the "Meeting"). A total of 5,375,071 common shares of the Company (the "Common Shares") were voted, representing 33.63% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
1/30/24 10:48:36 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board. "We are extremely privileged to have these leading experts on state-of-the art breast cancer cli
10/25/23 9:15:00 AM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2022 held on February 9, 2023 (the "Meeting"). A total of 6,663,370 common shares of the Company (the "Common Shares") were voted, representing 42.94% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
2/9/23 11:09:18 PM ET
$BCTX
Biotechnology: Pharmaceutical Preparations
Health Care

BriaCell Starts Patient Enrollment In First-in-Human Study Of Bria-OTS In Advanced Metastatic Breast Cancer

Chat with this insight

Recent Analyst Ratings for $BCTX

$BCTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by BriaCell Therapeutics Corp.

SEC Form SC 13D/A filed by BriaCell Therapeutics Corp. (Amendment)

SEC Form SC 13G/A filed by BriaCell Therapeutics Corp. (Amendment)

$BCTX Press Releases

Fastest customizable press release news feed in the world

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

$BCTX Leadership Updates

Live Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

$BCTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX Market Insights

Live Market Insights

BriaCell Reports Extended Progression-Free Survival To 9.1 Months In ADC Resistant Metastatic Breast Cancer Patient; Top Responder Continues Bria-IMT Treatment In Phase 2 Study

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

$BCTX SEC Filings

BriaCell Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

$BCTX Financials

Live finance-specific insights

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BCTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

Recent Analyst Ratings for
$BCTX

$BCTX
Large Ownership Changes

$BCTX
Press Releases

$BCTX
Leadership Updates

$BCTX
Insider Trading

$BCTX
Market Insights

$BCTX
SEC Filings

$BCTX
Financials

$BCTX
Analyst Ratings

$BCTX
Insider Purchases